Oral Anticoagulant Therapy of Human Cancer
Journal/Book: J Med. 1974; 5: 83-91.
Abstract: Continuous oral anticoagulant therapy, mainly with warfarin sodium, has been investigated for the prevention of the spread of cancer. Three separate clinical trials were conducted. The first with 96 patients to show the safety of anticoagulant therapy. The second used 30 patients as their own controls and showed that warfarin decreased by 75% the dosage of cytotoxic agents required for maintenance therapy of Hodgkins disease and chronic myeloid leukaemia. The third was a controlled trial involving 128 patients with various recurrent cancers. Warfarin was given in addition to conventional therapy. The 2-year survival was significantly higher in the warfarin group (40.6%) compared to controls (17.8%).